On May 7, 2018, the Company announced that it has acquired 23 approved and one pending drug product applications from a subsidiary of Endo International PLC (NASDAQ: ENDP) (“Endo”) for an upfront payment plus future milestone payments. The portfolio primarily consists of oral solutions with a few semi-solid products. Other financial terms were not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.